Italian Registry of Allergen ImmunoTherapy
ConditionAllergic Respiratory Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1+
SponsorSocietà Italiana di Allergologia, Asma e Immunologia Clinica
About this trial
RIAIT (Italian Registry of Allergy Immunotherapy) is a multicenter observational study that aims to prospectively collect the most extensive data available on Italian patients using AIT for respiratory allergies (rhinoconjunctivitis and/or asthma) in a real-life context, through a network of allergy centers with specific interest and expertise in the management of allergic respiratory patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 1 year
Confirmed diagnosis of allergic rhinoconjunctivitis and/or allergic asthma according to EAACI 2019 guidelines.
Having been followed by the recruiting center for at least one month: this is considered necessary to establish that the patients are truly affected by allergic respiratory disease and are eligible for allergen-specific immunotherapy; in this period, screening tests are carried out to exclude and/or confirm concomitant diseases (comorbidities). In fact, according to the aforementioned EAACI guidelines, a patient can be defined as truly eligible for allergen-specific immunotherapy only after a preliminary phase in which the patient is treated with symptomatic therapy; this observation period allows a correct evaluation of the real adherence and response to therapy, as well as the identification and appropriate treatment of any comorbidity and the possible elimination of aggravating factors.
Having received the prescription of any of the available AIT products in Italy, irrespectively of the selected allergens and the administration route and schedule.
Disqualifiers
None
Trial population
RIAIT is a prospective multicenter observational registry of patients suffering from conjunctivitis, rhinitis, and/or allergic asthma eligible for and treated with AIT according to EAACI (European Academy of Allergy and Clinical Immunology) Guidelines.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Life Quality as measured by Standardised Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ(S)) (≥12years)
Time frame
Every year to ten year2
Life Quality as measured by Paediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) For Children 6 - 12 years
Time frame
Every year to ten yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Società Italiana di Allergologia, Asma e Immunologia Clinica
Lead sponsor
Società Italiana di Allergologia e Immunologia Pediatrica (SIAIP)
Collaborator
Source ClinicalTrials.gov